Abstract
Life annuities markets are underdeveloped in Portugal and other countries. This annuitization puzzle is explained by improvements in mortality at old ages and passive adverse selection, reasons that put lives with diminished life expectancies at an unfair disadvantage. Using data from the SHARE (Survey of Health, Ageing and Retirement in Europe) project, we assess the impact of some of the most serious and common diseases over a reference survival curve. Then we calculate the price of annuities for impaired lives, using adjusted survival, and compare them with those for the reference population. We show that applying the reference mortality to impaired lives is very unfair and that pricing annuities for lives weakened by disease in an accurate way is possible.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
